Roche's Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients (Again)

The search for an effective treatment that can dampen the overactive immune systems in patients with COVID-19 continues unsuccessfully. The latest return victim: Roche's (OTC: RHHBY) Actemra, which failed a phase 3 study in hospitalized patients with severe COVID-19-associated pneumonia. In severe COVID-19 patients, it isn't the virus that's causing most of the serious symptoms but the overreaction of the patient's immune system that results in autoimmune damage.